uniQure Crescita futura
Criteri Future verificati 5/6
Si prevede che uniQure aumenterà gli utili e i ricavi rispettivamente del 62.4% e 56.2% all'anno, mentre si prevede che l'EPS crescerà del 62.2% all'anno.
Informazioni chiave
62.4%
Tasso di crescita degli utili
62.18%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 27.2% |
| Tasso di crescita dei ricavi | 56.2% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Good |
| Ultimo aggiornamento | 31 Jul 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Seeking Alpha • Jul 31
uniQure: 'Hold' AMT-130 U-Turn By FDA For HD Could Possibly Alter Course
Summary uniQure N.V. is downgraded to Hold from Strong Buy due to regulatory uncertainties for AMT-130 in Huntington's Disease. The FDA reversed its stance, now allowing a BLA filing for AMT-130 under accelerated approval, contingent on launching a phase 3 confirmatory trial and other measures. QURE plans to file the BLA in Q3 2026 and release 4-year phase 1/2 data in September 2026; UK regulatory filing is also targeted for Q3 2026. Ample cash reserves [$810.3M as of June 2026] support operations into 2030, but several hurdles remain before a bullish stance is warranted. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jul 30
QURE: Overvaluation Risks Persist As Single Huntington Filing Timeline Dominates
uniQure's updated analyst price target reflects a modest uplift in fair value to $36.30, supported by analysts' refreshed models around AMT-130's FDA-supported accelerated approval path and revised long term revenue and profitability assumptions. Analyst Commentary Recent Street research on uniQure shows a wide range of views, with many analysts updating their models around the AMT-130 program and the accelerated approval path.
Aggiornamento narrativa • Jul 02
QURE: FDA Reversal And 2026 BLA Plan Will Drive Huntington’s Outlook
Analysts have lifted the uniQure fair value estimate from about $52.56 to $64.47, citing recent FDA feedback on AMT-130 that, in their view, improves visibility on a potential accelerated approval path and supports higher modeled revenue growth with a lower assumed discount rate and P/E multiple. Analyst Commentary Recent Street research on uniQure has shifted sharply following the latest FDA Type B meeting on AMT-130, with multiple firms revising price targets and ratings after the company outlined plans for a potential accelerated approval filing.Articolo di analisi • Jun 20
uniQure (QURE) Stock Could Be 12% Undervalued After FDA Backs AMT 130 Filing Path
uniQure (NasdaqGS:QURE) is back in focus after the FDA said three year Phase I/II data for its Huntington’s disease gene therapy, AMT-130, can underpin a Biologics License Application for accelerated approval. See our latest analysis for uniQure. The FDA update has arrived after a sharp reset in sentiment around uniQure, with the stock posting a 90 day share price return of 187.69% and a 1 year total shareholder return of 225.76%. This points to strong positive momentum from a much lower...Aggiornamento narrativa • Jun 18
QURE: FDA Setback And 2026 Filings Will Shape Huntington’s Gene Therapy Path
The analyst price target for uniQure has been raised from about $39.05 to roughly $52.56. This reflects analysts' view that the planned biologics license application for AMT-130 in Huntington's disease and recent FDA feedback help support stronger long term revenue growth expectations and a higher future P/E multiple.Aggiornamento narrativa • Jun 03
QURE: FDA Shakeup And 2026 UK Filing Will Reshape Huntington’s Therapy Prospects
Analysts have adjusted their average price targets for uniQure in a mixed way, with some firms lifting targets by $1 to $49 and others trimming by $6 to $20. These changes largely reflect differing views on how recent FDA leadership changes may affect the regulatory path for AMT-130 and the broader pipeline.Aggiornamento narrativa • May 20
QURE: Shifting FDA Leadership Will Reopen Path For Huntington’s Gene Therapy Approval
uniQure's updated analyst price target of $39.05 reflects a modest upward reset, supported by analysts' mixed but generally constructive views on AMT-130's regulatory path and the broader gene therapy pipeline. Analyst Commentary Recent research on uniQure shows a split view, with some analysts turning more constructive after changes at the FDA, while others stay cautious given the regulatory uncertainty and development timelines around AMT-130.Articolo di analisi • May 08
uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Have Been Cutting Their Estimates
Shareholders will be ecstatic, with their stake up 21% over the past week following uniQure N.V. 's ( NASDAQ:QURE...Aggiornamento narrativa • May 03
QURE: FDA Leadership Shift Will Reshape Gene Therapy Approval Path
Analysts have lifted uniQure's price targets, with moves such as Chardan's $15 increase to $31 and Wells Fargo's $45 increase to $60. They cite an improved regulatory backdrop for AMT-130 and a reassessment of the company's risk and reward profile.Aggiornamento narrativa • Apr 09
QURE: Shifting FDA Leadership Will Reopen Rare Disease Gene Therapy Discussions
Analysts trimmed their average uniQure price target by $6, with the shift reflecting concern around the FDA's call for a sham surgery controlled Phase 3 trial for AMT-130, even as some research argues that recent regulatory leadership changes could improve the discussion around rare disease approvals. Analyst Commentary Recent research covers a wide spectrum of views on uniQure, with opinions clustered around how the FDA's stance on AMT-130 and agency leadership changes could influence valuation, timelines, and competitive positioning.Aggiornamento narrativa • Mar 24
QURE: Evolving FDA Leadership Will Shape Future Gene Therapy Upside
The updated analyst price target for uniQure moves higher to around $38, supported by analysts who see improved regulatory prospects for AMT-130 and the broader pipeline following recent FDA leadership changes, even as views on timelines and trial requirements remain mixed. Analyst Commentary Recent research shows a sharp split in how analysts think about uniQure, with some pointing to a more flexible regulatory backdrop as a key upside driver and others staying focused on trial risk, ethics concerns, and competitive pressure in Huntington's disease.Aggiornamento narrativa • Mar 07
QURE: Future FDA Trial Resolution Will Drive Gene Therapy Upside
Analysts have cut their fair value estimate for uniQure from about $53.54 to $28.67 as they reassess the impact of the FDA's push for a randomized, sham-controlled Phase 3 trial for AMT-130. They are applying a higher discount rate, moderating revenue growth and profit margin assumptions, and using a much higher future P/E multiple to reflect greater uncertainty in the path to commercialization.Aggiornamento narrativa • Feb 21
QURE: Future Huntington’s FDA Decisions Will Drive Gene Therapy Upside
Analysts have trimmed their fair value estimate for uniQure to about $53.54 from roughly $54.42. This reflects slightly higher discount rate assumptions and modest tweaks to growth and margin expectations after recent neutral Street research coverage.Aggiornamento narrativa • Feb 07
QURE: Future FDA Path On Huntington’s Program Will Drive Gene Therapy Upside
Analysts have trimmed their fair value estimate for uniQure from about $55.27 to $54.42. This reflects updated views on discount rates, revenue growth, profit margins and future P/E following recent neutral Street research coverage.Aggiornamento narrativa • Jan 21
QURE: Future FDA Clarity On Huntington’s Data Requirements Will Drive Gene Therapy Upside
Narrative Update Analysts have trimmed their fair value estimate for uniQure only slightly, with the implied price target moving lower by a few dollars as they factor in a higher discount rate, modestly stronger profit margin assumptions, and fresh regulatory uncertainty around AMT-130 following recent FDA feedback and price target cuts from several firms. Analyst Commentary Street research on uniQure is clustered around the FDA’s shift on AMT-130 in Huntington’s disease, and what that means for valuation, risk, and timing.Aggiornamento narrativa • Jan 07
QURE: Future Regulatory Clarity On Huntington’s Pathway Will Drive Gene Therapy Upside
Narrative Update: uniQure Analysts have cut their price targets on uniQure, with one moving from US$56 to US$38, another from US$76 to US$53, and a third from US$65 to US$45. These changes reflect concerns about the FDA's decision not to support a BLA filing for AMT-130 in Huntington's disease based on current Phase 1/2 data and the resulting uncertainty around the program's regulatory path and timing.Aggiornamento narrativa • Dec 17
QURE: Future Regulatory Clarity Will Drive Gene Therapy Upside Despite FDA Setback
The analyst price target for uniQure has been reduced from $56 to $38 as analysts factor in heightened regulatory uncertainty around AMT-130, a higher perceived discount rate, and more conservative revenue growth expectations, despite still-supportive long term Huntington's disease data. Analyst Commentary Analyst views on uniQure have shifted rapidly from optimism following the three year AMT 130 data to caution after the FDA withdrew support for a BLA based on the current Phase 1 2 package.Aggiornamento narrativa • Dec 03
QURE: Future Regulatory Clarity Will Unlock Gene Therapy Upside Despite Delays
Analysts have modestly reduced their average price target for uniQure, reflecting greater regulatory uncertainty and a longer timeline to monetize AMT-130 in Huntington's disease, while still recognizing meaningful long term revenue growth potential. Analyst Commentary Recent Street research reflects a sharp swing from earlier optimism to a more balanced and risk aware stance on uniQure, with price targets reset lower but not uniformly bearish.Aggiornamento narrativa • Nov 19
QURE: Regulatory Path Clarity Will Drive Share Recovery After Recent FDA Setback
uniQure's analyst price target has been lowered notably, with estimates now around $38 to $58 per share from previous targets as high as $76, as analysts cite increased regulatory uncertainty following the FDA's recent withdrawal of support for AMT-130's current data package in Huntington's disease. Analyst Commentary Recent street research offers a wide range of perspectives on uniQure’s outlook following regulatory setbacks and key data releases.Aggiornamento narrativa • Nov 01
QURE: Pivotal Three-Year Huntington’s Data Will Drive Approval and Market Uptake
uniQure's analyst price targets have been raised substantially, with increases ranging from $24 to as high as $80 per share. Analysts cite strong three-year Huntington's disease trial data and growing confidence in the approval and impact of AMT-130.Aggiornamento narrativa • Oct 18
AMT-130 Approval Will Transform Huntington's Treatment Pipeline
Analysts have raised their price target for uniQure from approximately $66 to $75 per share. They cite strong three-year AMT-130 data in Huntington's disease, as well as increased confidence in the therapy's clinical profile and approval pathway.Aggiornamento narrativa • Oct 04
AMT-130 Approval Will Transform Huntington's Treatment Pipeline
uniQure's analyst price targets have surged, with fair value estimates nearly doubling from around $35 to $66 per share. Analysts point to robust, statistically significant AMT-130 data in Huntington's disease, which supports higher revenue growth expectations and dramatically improved profitability assumptions.Aggiornamento narrativa • Sep 18
AMT-130 Approval Will Transform Huntington's Treatment Pipeline
uniQure’s consensus price target was revised down from $36.96 to $34.94 as analysts balance optimism around AMT-130’s differentiated approach and near-term data catalysts with procedural concerns and selling pressure, resulting in a modest fair value decrease. Analyst Commentary Bullish analysts view the recent share selloff driven by absence of AMT-130 Phase 1/2 three-year data as a buying opportunity, emphasizing management’s reassurance that the data remains on schedule for September.Aggiornamento narrativa • Aug 27
AMT-130 Approval Will Transform Huntington's Treatment Pipeline
The consensus Analyst Price Target for uniQure has risen to $36.96, reflecting increased optimism for AMT-130’s commercial potential and near-term regulatory catalysts, supported by a strong cash position and resolution of technical valuation concerns. Analyst Commentary Bullish analysts see AMT-130 as a potential dominant therapy in Huntington's disease, not susceptible to AAV-related acute liver failure concerns due to direct brain administration.Nuova narrativa • May 11
AMT-130 Approval Will Transform Huntington's Treatment Pipeline
Accelerated approval of AMT-130 for Huntington's could significantly boost future revenues as it would be a pioneering treatment.Articolo di analisi • May 10
Is uniQure (NASDAQ:QURE) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Apr 19
uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting
Summary uniQure's AMT-130 gene therapy showed an 80% slowing of Disease progression in Huntington's Disease patients in a phase 1/2 study. Financially strong with $448 million in cash, uniQure can fund operations through H2 2027, reducing immediate financial risk. AMT-191 for Fabry Disease and AMT-162 for ALS are also advancing, diversifying uniQure's pipeline and potential market impact. FDA type B meeting to be held in Q2 of 2025 to discuss the possibility of Accelerated Approval of AMT-130 for the treatment of patients with HD. Read the full article on Seeking AlphaSeeking Alpha • Feb 20
uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons
Summary uniQure's gene therapy AMT-130 for Huntington's Disease shows promising clinical data, with an 80% reduction in disease progression, positioning it for potential FDA approval. Despite past commercial failures, uniQure's current market cap of ~$715m appears undervalued given AMT-130's estimated peak sales potential of ~$2bn. The company has a solid cash position to fund AMT-130's launch, with $251m in cash and $183m in securities, despite a $100m net loss in the first 9m of 2025. uniQure's strategic moves, including selling its Lexington facility and reducing cash burn, indicate a strong, focused approach towards achieving commercial success with AMT-130. Read the full article on Seeking AlphaSeeking Alpha • Dec 10
uniQure's AMT-130: A Bold Step For Huntington's, But Not Without Hurdles
Summary uniQure N.V.'s AMT-130 demonstrated an 80% reduction in disease progression for high-dose patients, supported by biomarker data. Huntington's disease affects 41,000 people in the U.S., and the market is projected to grow to $3 billion by 2032, underscoring significant demand. If approved, AMT-130 faces adoption challenges due to its invasive brain surgery delivery and high cost, typical of gene therapies. uniQure's cash position and royalties from Hemgenix sales provide some financial stability, enabling continued pipeline development. Despite AMT-130's promise, commercialization challenges, cash burn, and strong competition from oral options like PTC518 warrant a cautious investment stance (“hold”). Read the full article on Seeking AlphaArticolo di analisi • Dec 07
Is There An Opportunity With uniQure N.V.'s (NASDAQ:QURE) 39% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, uniQure fair value estimate is US$12.16 Current share price of...Seeking Alpha • Oct 21
uniQure's Yellow Flags: Early-Stage Gene Therapies Amid Restructuring
Summary uniQure N.V. leverages AAV technology to develop gene therapies for liver and CNS diseases, with one FDA-approved treatment and multiple investigational drugs in its pipeline. Despite promising technology and an FDA Orphan Drug designation for AMT-191, QURE's early-stage pipeline and ongoing restructuring add significant risk. The Company's valuation appears slightly high relative to peers, with limited upside potential, making it prudent to rate the stock as a "Hold" for now. Monitoring QURE's next quarterly report is crucial to assess the impact of its restructuring and potential progress in its pipeline. Read the full article on Seeking AlphaSeeking Alpha • Aug 06
uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity
Summary uniQure N.V. released positive 24-month trial data for AMT-130 gene therapy for Huntington's Disease, leading to a significant stock price increase. The company has aggressively restructured to extend its cash runway, focusing on AMT-130 development with confidence in its success. Despite risks, including potential negative trial data, its strong balance sheet and upcoming catalysts make it possible for QURE stock to reach $15 by year-end. Read the full article on Seeking AlphaArticolo di analisi • Aug 03
uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know
uniQure N.V. ( NASDAQ:QURE ) just released its quarterly report and things are looking bullish. Overall results were...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 378 | -58 | -93 | -98 | 8 |
| 12/31/2027 | 130 | -212 | -199 | -143 | 10 |
| 12/31/2026 | 25 | -262 | -175 | -225 | 11 |
| 6/30/2026 | 19 | -252 | -161 | -161 | N/A |
| 3/31/2026 | 18 | -209 | -173 | -172 | N/A |
| 12/31/2025 | 16 | -199 | -178 | -178 | N/A |
| 9/30/2025 | 16 | -235 | -154 | -153 | N/A |
| 6/30/2025 | 14 | -199 | -174 | -173 | N/A |
| 3/31/2025 | 20 | -218 | -167 | -166 | N/A |
| 12/31/2024 | 27 | -240 | -186 | -183 | N/A |
| 9/30/2024 | 29 | -240 | -185 | -179 | N/A |
| 6/30/2024 | 28 | -285 | -111 | -104 | N/A |
| 3/31/2024 | 19 | -297 | -135 | -128 | N/A |
| 12/31/2023 | 16 | -308 | -153 | -146 | N/A |
| 9/30/2023 | 112 | -228 | -161 | -151 | N/A |
| 6/30/2023 | 112 | -187 | -251 | -239 | N/A |
| 3/31/2023 | 110 | -157 | -214 | -198 | N/A |
| 12/31/2022 | 106 | -127 | -163 | -145 | N/A |
| 9/30/2022 | 61 | -125 | -154 | -137 | N/A |
| 6/30/2022 | 62 | -114 | -149 | -129 | N/A |
| 3/31/2022 | 525 | 324 | 286 | 304 | N/A |
| 12/31/2021 | 524 | 330 | 271 | 288 | N/A |
| 9/30/2021 | 500 | 321 | 281 | 298 | N/A |
| 6/30/2021 | 500 | 303 | 292 | 303 | N/A |
| 3/31/2021 | 38 | -139 | -154 | -143 | N/A |
| 12/31/2020 | 38 | -125 | -144 | -135 | N/A |
| 9/30/2020 | 6 | -166 | -132 | -124 | N/A |
| 6/30/2020 | 5 | -136 | -120 | -111 | N/A |
| 3/31/2020 | 6 | -124 | N/A | -105 | N/A |
| 12/31/2019 | 7 | -124 | N/A | -99 | N/A |
| 9/30/2019 | 6 | -105 | N/A | -91 | N/A |
| 6/30/2019 | 8 | -103 | N/A | -89 | N/A |
| 3/31/2019 | 9 | -92 | N/A | -81 | N/A |
| 12/31/2018 | 11 | -83 | N/A | -76 | N/A |
| 9/30/2018 | 12 | -90 | N/A | -76 | N/A |
| 6/30/2018 | 11 | -78 | N/A | -71 | N/A |
| 3/31/2018 | 13 | -78 | N/A | -74 | N/A |
| 12/31/2017 | 13 | -79 | N/A | -64 | N/A |
| 9/30/2017 | 20 | -67 | N/A | -62 | N/A |
| 6/30/2017 | 25 | -72 | N/A | -65 | N/A |
| 3/31/2017 | 24 | -71 | N/A | -68 | N/A |
| 12/31/2016 | 25 | -73 | N/A | -72 | N/A |
| 9/30/2016 | 20 | -76 | N/A | -81 | N/A |
| 6/30/2016 | 16 | -90 | N/A | -62 | N/A |
| 3/31/2016 | 14 | -90 | N/A | 5 | N/A |
| 12/31/2015 | 11 | -82 | N/A | 7 | N/A |
| 9/30/2015 | 8 | -76 | N/A | 22 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che QURE diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 3.5% ).
Guadagni vs Mercato: Si prevede che QURE diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.
Guadagni ad alta crescita: Si prevede QURE diventerà redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di QURE ( 56.2% all'anno) crescerà più rapidamente del mercato US ( 12.8% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di QURE ( 56.2% all'anno) crescerà più rapidamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di QURE è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/05 17:35 |
| Prezzo dell'azione a fine giornata | 2026/08/05 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
uniQure N.V. è coperta da 32 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Madhu Kumar | Baird |
| Eliana Merle | Barclays |
| Vincent Chen | Bernstein |